Stevens Capital Management’s Emergent Biosolutions EBS Stock Holding History

Stevens Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-23,806	Closed	-$691K	–	894
2017 Q1	$691K	Buy	+23,806	New	+$725K	0.03%	504
2016 Q3	–	Sell	-8,107	Closed	-$228K	–	954
2016 Q2	$228K	Buy	+8,107	New	+$318K	0.01%	743
2015 Q4	–	Sell	-16,881	Closed	-$481K	–	974
2015 Q3	$481K	Buy	+16,881	New	+$556K	0.02%	544
2015 Q2	–	Sell	-16,735	Closed	-$481K	–	1075
2015 Q1	$481K	Buy	+16,735	New	+$480K	0.02%	591
2013 Q4	–	Sell	-13,894	Closed	-$265K	–	1057
2013 Q3	$265K	Buy	+13,894	New	+$248K	0.01%	828

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Stevens Capital Management's EBS Position: Q2 2017 in Review

Stevens Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2017, closing a stake of 23,806 shares — an estimated $691K sold.

Stevens Capital Management first reported a position in EBS in Q3 2013 and held it in 5 quarters. The position peaked at $691K in Q1 2017. 181 funds tracked by Wall St. Rank hold EBS as of Q2 2017.

Stevens Capital Management reported no remaining Emergent Biosolutions position as of Q2 2017 after selling out during the quarter.
Stevens Capital Management sold 23,806 Emergent Biosolutions shares in Q2 2017, an estimated $691K.
Stevens Capital Management first reported a position in Emergent Biosolutions in Q3 2013 and held it in 5 quarters.
Stevens Capital Management's Emergent Biosolutions position peaked at $691K in Q1 2017.
181 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2017.

Based on Stevens Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.